PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE
Aim. To study therapeutic equivalence of rosuvastatin generic and original medication and to conduct the pharmacoeconomic analysis to compare the impact of the drug on direct expenses in secondary prevention for the patients with chronic ischemic heart disease (CHD). Material and methods. The open l...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«SILICEA-POLIGRAF» LLC
2015-08-01
|
| Series: | Кардиоваскулярная терапия и профилактика |
| Subjects: | |
| Online Access: | https://cardiovascular.elpub.ru/jour/article/view/244 |
| _version_ | 1797882506040573952 |
|---|---|
| author | E. I. Tarlovskaya G. I. Nechaeva S. V. Malchikova А. А. Semenkin |
| author_facet | E. I. Tarlovskaya G. I. Nechaeva S. V. Malchikova А. А. Semenkin |
| author_sort | E. I. Tarlovskaya |
| collection | DOAJ |
| description | Aim. To study therapeutic equivalence of rosuvastatin generic and original medication and to conduct the pharmacoeconomic analysis to compare the impact of the drug on direct expenses in secondary prevention for the patients with chronic ischemic heart disease (CHD). Material and methods. The open label, prospective observational study performed with the switch of medication, that included 38 patients with chronic CHD and duration of 6 months. During 3 months the patients received original drug rosuvastatin Crestor 10-20 mg, leading to the target level of low density cholesterol <1,8 mmol/L. Then the switch done, and generic drug prescribed for 3 months — Rosart (Actavis) in analogous doses. Patients were investigated at the baseline, in 3 and 6 months. Lipid spectrum parameters were measured, C-reactive protein, transaminases and creatinekinase, bilirubin, glucose, creatinine. Evaluation of clinical and economic efficacy of original and generic rosuvastatine was done by modelling. The direct medical expenses were calculated for the usage of medical resources for emergent, outpatient and inpatient care for cardiovascular pathology. For the forecast of cardiovascular events probability and their consequences with associated direct medicalexpenses by the period of time using various therapeutic strategies we used Markov model developed by Belousov et al. (2011). Results. Generic drug Rosart does not show minority by hypolipidemic, anti-inflammatory effects and safety criteria comparing to the original Crestor. Short-term (1 year) prescription of rosuvastatin (Rosart and Crestor equally) increases life duration by 0,99 years; middle-term (5 years) by 4,25 years; long-term (10 years) — by 6,82 and 6,85 years, respectively. Conclusion. The main result of the modelled pharmacoeconomic analysis of the influence of generic and original rosuvastatin on the direct and indirect medical expenses for secondary prevention in chronic ischemic heart disease is a conclusion that the most effective for expenses in the aim-fulfillment is generic rosuvastatin. |
| first_indexed | 2024-04-10T03:35:48Z |
| format | Article |
| id | doaj.art-086395e2c34d4c9982febb539a427724 |
| institution | Directory Open Access Journal |
| issn | 1728-8800 2619-0125 |
| language | Russian |
| last_indexed | 2024-04-10T03:35:48Z |
| publishDate | 2015-08-01 |
| publisher | «SILICEA-POLIGRAF» LLC |
| record_format | Article |
| series | Кардиоваскулярная терапия и профилактика |
| spelling | doaj.art-086395e2c34d4c9982febb539a4277242023-03-13T07:23:24Zrus«SILICEA-POLIGRAF» LLCКардиоваскулярная терапия и профилактика1728-88002619-01252015-08-01144293710.15829/1728-8800-2015-4-29-37243PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASEE. I. Tarlovskaya0G. I. Nechaeva1S. V. Malchikova2А. А. Semenkin3ГБОУ ВПО Нижегородская государственная медицинская академия Минздрава России. Нижний Новгород, РоссияГБОУ ВПО Омский государственный медицинский университет Минздрава России. Омск, РоссияГБОУ ВПО Кировская государственная медицинская академия Минздрава России. Киров, РоссияГБОУ ВПО Омский государственный медицинский университет Минздрава России. Омск, РоссияAim. To study therapeutic equivalence of rosuvastatin generic and original medication and to conduct the pharmacoeconomic analysis to compare the impact of the drug on direct expenses in secondary prevention for the patients with chronic ischemic heart disease (CHD). Material and methods. The open label, prospective observational study performed with the switch of medication, that included 38 patients with chronic CHD and duration of 6 months. During 3 months the patients received original drug rosuvastatin Crestor 10-20 mg, leading to the target level of low density cholesterol <1,8 mmol/L. Then the switch done, and generic drug prescribed for 3 months — Rosart (Actavis) in analogous doses. Patients were investigated at the baseline, in 3 and 6 months. Lipid spectrum parameters were measured, C-reactive protein, transaminases and creatinekinase, bilirubin, glucose, creatinine. Evaluation of clinical and economic efficacy of original and generic rosuvastatine was done by modelling. The direct medical expenses were calculated for the usage of medical resources for emergent, outpatient and inpatient care for cardiovascular pathology. For the forecast of cardiovascular events probability and their consequences with associated direct medicalexpenses by the period of time using various therapeutic strategies we used Markov model developed by Belousov et al. (2011). Results. Generic drug Rosart does not show minority by hypolipidemic, anti-inflammatory effects and safety criteria comparing to the original Crestor. Short-term (1 year) prescription of rosuvastatin (Rosart and Crestor equally) increases life duration by 0,99 years; middle-term (5 years) by 4,25 years; long-term (10 years) — by 6,82 and 6,85 years, respectively. Conclusion. The main result of the modelled pharmacoeconomic analysis of the influence of generic and original rosuvastatin on the direct and indirect medical expenses for secondary prevention in chronic ischemic heart disease is a conclusion that the most effective for expenses in the aim-fulfillment is generic rosuvastatin.https://cardiovascular.elpub.ru/jour/article/view/244розувастатинстабильная ишемическая болезнь сердцатерапевтическая эквивалентностьфармакоэкономиче ский анализ |
| spellingShingle | E. I. Tarlovskaya G. I. Nechaeva S. V. Malchikova А. А. Semenkin PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE Кардиоваскулярная терапия и профилактика розувастатин стабильная ишемическая болезнь сердца терапевтическая эквивалентность фармакоэкономиче ский анализ |
| title | PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE |
| title_full | PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE |
| title_fullStr | PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE |
| title_full_unstemmed | PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE |
| title_short | PREDICTION OF THE INFLUENCE OF ORIGINAL AND GENERIC ROSUVASTATIN ON DIRECT MEDICAL COSTS OF SECONDARY PREVENTION IN PATIENTS WITH CHRONIC TYPES OF ISCHEMIC HEART DISEASE |
| title_sort | prediction of the influence of original and generic rosuvastatin on direct medical costs of secondary prevention in patients with chronic types of ischemic heart disease |
| topic | розувастатин стабильная ишемическая болезнь сердца терапевтическая эквивалентность фармакоэкономиче ский анализ |
| url | https://cardiovascular.elpub.ru/jour/article/view/244 |
| work_keys_str_mv | AT eitarlovskaya predictionoftheinfluenceoforiginalandgenericrosuvastatinondirectmedicalcostsofsecondarypreventioninpatientswithchronictypesofischemicheartdisease AT ginechaeva predictionoftheinfluenceoforiginalandgenericrosuvastatinondirectmedicalcostsofsecondarypreventioninpatientswithchronictypesofischemicheartdisease AT svmalchikova predictionoftheinfluenceoforiginalandgenericrosuvastatinondirectmedicalcostsofsecondarypreventioninpatientswithchronictypesofischemicheartdisease AT aasemenkin predictionoftheinfluenceoforiginalandgenericrosuvastatinondirectmedicalcostsofsecondarypreventioninpatientswithchronictypesofischemicheartdisease |